CONVIDECIA
Product Overview
Type: COVID-19 Vaccine (Ad5-nCoV-S [Recombinant])
INN: N/A
Commercial name: Convidecia
EUL holder: CanSino Biologics Inc.
Country: People’s Republic of China
Responsible NRA: National Medical Products Administration (NMPA)
Country: People’s Republic of China
WHO EUL recommendation
Effective date: 19 May 2022
Recommendation for an Emergency Use Listing (EUL) of Convidecia COVID-19 Vaccine (Ad5/nCoV-5[recombinant]) submitted by CanSino Biologics Inc. (Published: 10 October 2022)
Product description
Pharmaceutical Form: Sterile solution for injection
Presentation: 2 mL / Vial
Number of doses: 1 and 3 doses of 0.5 mL
Route of administration: Intramuscular
Age indication: Individuals 18 to 59 years of age
Shelf – life: 12 months
Storage temperature: 2°C to 8°C
Vaccine Vial monitor (VVM): None
Preservative: None
Diluent: None
Special storage conditions: Not applicable
Handling of opened multi-dose vials:
WHO recommends that opened vials of this vaccine should be discarded 6 hours after opening or at the end of the immunization session, whichever comes first.
Packaging description
Secondary Packaging: |
Box containing 40 vials (40 doses). Dimensions: 4.4 x 15.6 x 9.5 cm |
Tertiary Packaging: |
a. Carton containing 18 secondary boxes (58 vials/720 doses). Dimensions: 17x49.3x21.7 cm. b. Carton containing 30 secondary boyes (1200 vials/1200 doses). Dimensions: 25.5x34x31.5 cm. |
Cold Chain Volume: | 16.30 cm3/dose (in secondary packaging) |